American Diabetes Association 77th Scientific Sessions ADA 2017 Category Document: Notable Orals
This category document features our top individual abstract picks – 40 in total – from ADA 2017’s 49 oral presentation sessions (each session has at least ten orals). This is up from 23 notable orals at ADA 2016. The abstract titles below are sorted by category (Diabetes Therapy, Diabetes Technology) and listed in numerical order by abstract ID number.
Please note that this document does not include symposia presentations that will also feature new data, such as results from the CANVAS (3-CT-SY26) and DEVOTE (3-CT-SY22) cardiovascular outcomes trials (CVOTs) for J&J’s Invokana (canagliflozin) and Novo Nordisk’s Tresiba (insulin degludec), findings from several type 1 diabetes immune intervention trials including TrialNet’s oral insulin study (5-IT-SY07), additional data from the LEADER CVOT (1-AC-SY13) for Novo Nordisk’s Victoza (liraglutide), results from the ODYSSEY DM program investigating Sanofi’s PCSK9 inhibitor Praluent (alirocumab) in people with diabetes (1-AC-SY12), and a long-awaited look at the JDRF-sponsored REMOVAL trial of metformin in type 1 diabetes (3-CT-SY23). See our ADA 2017 preview for a more detailed look at each of these sessions and the rest of the meeting’s notable sessions.
Some of the most notable orals related to diabetes therapy are concentrated in four sessions: (i) GLP-1s and SGLT2s – To Do or Not to Do in Type 1 Diabetes Mellitus? (Saturday, 8:00 – 10:00 AM); (ii) Landscape of Therapeutic Trials in Type 2 Diabetes (Saturday, 4:00 – 6:00 PM); (iii) Translating Therapeutics to the Real World (Sunday, 8:00 – 10:00 AM); and, of course, (iv) ADA Presidents Oral Session (Tuesday, 9:45 – 11:45 AM).
In diabetes technology, the two main sessions to watch out for are Where is Glucose Monitoring Taking Us? (Saturday, 8:00 – 10:00 AM) and Pumps and Loops (Monday, 8:00 – 10:00 AM). We’ll also notable results on the digital health front in Thinking and Working Outside the Box – Prevention and Intervention Approaches (Sunday, 8:00 – 10:00 AM) and Venturing Beyond the Bricks, Mortar, and Books (Monday, 4:30 – 6:30 PM).
There are many orals of high importance not included here – we’ve done our best to select the most notable orals and provide a brief list, but much is of course subjective. Please write us if an oral presentation you are looking forward to is missing from this list!
- The ADA offers an online itinerary planner and mobile app that you can use to search for sessions and abstracts as well as organize your conference schedule. Each Abstract ID in this document has been hyperlinked to the session’s page on the itinerary planner to help you assemble your personal schedule.
- Embargoed abstracts are now live on the ADA itinerary planner. Please note - while the abstracts are publicly available on the ADA itinerary planner (and linked to in our category documents), they are still under embargo until the ADA meeting. Please see the ADA embargo policy for specifics on when individual embargoes lift.
- For more recommendations on how to make the best use of our Category Documents, see our “What is a Category Document” tip sheet.
Diabetes Therapy
|
Abstract ID |
Abstract Title |
Authors |
Room |
Day |
Date |
Time |
|
Effect of Empagliflozin (EMPA) on Anthropometry and Markers of Visceral and Total Adiposity by Age, Sex, and Degree of Abdominal Obesity in Patients with Type 2 Diabetes (T2D) and Cardiovascular Disease (CVD): EMPA-REG OUTCOME |
IAN J. NEELAND, DARREN K. MCGUIRE, MICHAELA MATTHEUS, HANS JUERGEN WOERLE, ODD ERIK JOHANSEN, DAVID FITCHETT, Dallas, TX, Ingelheim, Germany, Asker, Norway, Toronto, ON, Canada |
6DE |
Friday |
9-Jun |
5:45 - 6:00 PM |
|
|
Twenty-Four-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes (inTandem1) |
JOHN B. BUSE, SATISH K. GARG, JULIO ROSENSTOCK, PHILLIP BANKS, SANGEETA SAWHNEY, PAUL STRUMPH, Chapel Hill, NC, Aurora, CO, Dallas, TX, The Woodlands, TX |
Hall A |
Saturday |
10-Jun |
8:00 - 8:15 AM |
|
|
A 12-Week Dose-Ranging Study of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes (inTandem4) |
CLAIRE BAKER, SUMAN WASON, PHILLIP BANKS, SANGEETA SAWHNEY, PAUL STRUMPH, Omaha, NE, The Woodlands, TX |
Hall A |
Saturday |
10-Jun |
8:15 - 8:30 AM |
|
|
Efficacy and Safety of Liraglutide in Insulin-Pump-Treated People with Type 1 Diabetes: The Lira Pump Trial |
THOMAS F. DEJGAARD, CHRISTIAN S. FRANDSEN, SIGNE SCHMIDT, DORTE VISTISEN, STEN MADSBAD, HENRIK U. ANDERSEN, KIRSTEN NØRGAARD, Gentofte, Denmark, Hvidovre, Denmark |
Hall A |
Saturday |
10-Jun |
8:30 - 8:45 AM |
|
|
Safety and Efficacy of Ertugliflozin plus Sitagliptin vs. Either Treatment Alone after 52 Weeks in Subjects with T2DM Inadequately Controlled on Metformin: VERTIS FACTORIAL Trial Extension |
RICHARD E. PRATLEY, ANNASWAMY RAJI, ROY ELDOR, SHEILA SUNGA, YANPING QIU, JEREMY JOHNSON, SUSAN HUYCK, GREGORY GOLM, STEVEN G. TERRA, JAMES P. MANCUSO, SAMUEL S. ENGEL, BRETT LAURING, Orlando, FL, Kenilworth, NJ, Beijing, China, Andover, MA, Groton, CT |
Ballroom 20A-C |
Saturday |
10-Jun |
4:15 - 4:30 PM |
|
|
Efficacy and Safety of Exenatide QW vs. Placebo Added to Insulin Glargine in Uncontrolled Basal-Insulin Treated Type 2 Diabetes: DURATION-7 Trial |
JUAN P. FRÍAS, JULIO ROSENSTOCK, ANIKό SOMOGYI, SERGE A. JABBOUR, HUI WANG, ELISE HARDY, CRISTIAN GUJA, Los Angeles, CA, Dallas, TX, Budapest, Hungary, Philadelphia, PA, Gaithersburg, MD, Bucharest, Romania |
Ballroom 20A-C |
Saturday |
10-Jun |
4:45 - 5:00 PM |
|
|
Safety and Efficacy of Ertugliflozin after 52 Weeks in Subjects with T2DM Inadequately Controlled on Metformin and Sitagliptin: Results from the Extension Phase of the VERTIS SITA2 Trial |
JIE LIU, ROY ELDOR, SAMUEL DAGOGO-JACK, GUILLERMO AMORIN, JEREMY JOHNSON, YUQIN (ALICE) LIAO, SUSAN HUYCK, GREGORY GOLM, STEVEN G. TERRA, JAMES P. MANCUSO, SAMUEL S. ENGEL, BRETT LAURING, Kenilworth, NJ, Memphis, TN, Buenos Aires, Argentina, Beijing, China, Andover, MA, Groton, CT |
Ballroom 20A-C |
Saturday |
10-Jun |
5:00 - 5:15 PM |
|
|
Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) vs. Basal-Bolus (BB) Therapy in Patients with Type 2 Diabetes (T2D): DUAL VII Trial |
LIANA K. BILLINGS, ANKUR DOSHI, DIDIER GOUET, ALEJANDRA OVIEDO, HELENA W. RODBARD, NIKOLAOS TENTOLOURIS, RANDI GRØN, NATALIE HALLADIN, ESTEBAN JODAR, Evanston, IL, Houston, TX, La Rochelle, France, Buenos Aires, Argentina, Rockville, MD, Athens, Greece, Søborg, Denmark, Madrid, Spain |
Ballroom 20A-C |
Saturday |
10-Jun |
5:45 - 6:00 PM |
|
|
PREVENT-DM Comparative Effectiveness Trial of Lifestyle Intervention and Metformin |
MATTHEW J. O'BRIEN, ALBERLY PEREZ, ADAM SCANLAN, VICTOR A. ALOS, ROBERT C. WHITAKER, GARY D. FOSTER, RONALD T. ACKERMANN, JODY D. CIOLINO, CAROL J. HOMKO, Chicago, IL, Philadelphia, PA, New York, NY |
5 |
Sunday |
11-Jun |
8:00 - 8:15 AM |
|
|
Effect of Metformin on Diabetes Prevention at 15 Years: Identification of Subgroups Most Likely to Benefit, Diabetes Prevention Program (DPP) Research Group |
DAVID M. NATHAN, JILL P. CRANDALL, DANA DABELEA, SHARON L. EDELSTEIN, RONALD B. GOLDBERG, STEVEN E. KAHN, WILLIAM C. KNOWLER, KIEREN J. MATHER, XAVIER PI-SUNYER, MARINELLA TEMPROSA, GILDA TRANDAFIRESCU, ELIZABETH A. WALKER, DIABETES PREVENTION PROGRAM RESEARCH GROUP, Boston, MA, Bronx, NY, Aurora, CO, Rockville, MD, Miami, FL, Seattle, WA, Phoenix, AZ, Indianapolis, IN, New York, NY |
Hall A |
Saturday |
10-Jun |
8:00 - 8:15 AM |
|
|
The Value Index Favors Using GLP-1 More than DPP-4, Saving Medicare $200 Million |
SAAD SAKKAL, Mason, OH |
Hall A |
Saturday |
10-Jun |
8:15 - 8:30 AM |
|
|
PB-718, a Dual GLP-1/Glucagon Receptor Agonist Demonstrates Superior Weight-Loss Effect and Ameliorates Nonalcoholic Steatohepatitis (NASH) in Animal Models |
WEI LU, CHUNMEI WANG, XIAOSU LUO, YINGHUI ZHANG, LIANG HONG, MICHAEL XU, Suzhou, China |
31 |
Sunday |
11-Jun |
9:15 - 9:30 AM |
|
|
Semaglutide Provides Superior Body Weight Reduction across SUSTAIN 1-5 Clinical Trials |
ILDIKO LINGVAY, JÖRG LÜDEMANN, MICHEL MARRE, KARI UUSINARKAUS, VINCENT WOO, HENRIK F. THOMSEN, NELUN WIJAYASINGHE, MELANIE DAVIES, Dallas, TX, Falkensee, Germany, Paris, France, Colorado Springs, CO, Winnipeg, MB, Canada, Aalborg, Denmark, Søborg, Denmark, Leicester, United Kingdom |
Ballroom 20D |
Sunday |
11-Jun |
5:30 - 5:45 PM |
|
|
Body Weight and Energy Intake Changes in Overweight Individuals Treated with Canagliflozin, Phentermine, or Canagliflozin + Phentermine |
DAVID POLIDORI, NATHAN P. GILL, FRANK VERCRUYSSE, NGOZI ERONDU, KEVIN D. HALL, San Diego, CA, Bethesda, MD, Beerse, Belgium, Raritan, NJ |
25 |
Monday |
12-Jun |
9:45 - 10:00 AM |
|
|
Severe Hypoglycemia, Cardiovascular Outcomes, and Death—The LEADER Experience |
BERNARD ZINMAN, STEVEN P. MARSO, ERIK CHRISTIANSEN, SALVATORE CALANNA, SØREN RASMUSSEN, JOHN B. BUSE, Toronto, ON, Canada, Kansas City, KS, Søborg, Denmark, Chapel Hill, NC |
31 |
Monday |
12-Jun |
5:00 - 5:15 PM |
|
|
Hospitalization for Heart Failure and Death in New Users of SGLT2 Inhibitors in Patients With and Without Cardiovascular Disease—CVD-REAL Study |
MATTHEW A. CAVENDER, ANNA NORHAMMAR, KÅRE I. BIRKELAND, MARIT EIKA JØRGENSEN, JOHN P.H. WILDING, KAMLESH KHUNTI, ALEX Z. FU, JOHAN BODEGARD, BETINA T. BLAK, ERIC T. WITTBRODT, MARCUS THURESSON, PETER FENICI, NIKLAS HAMMAR, MIKHAIL N. KOSIBOROD, THE CVD-REAL INVESTIGATORS AND STUDY GROUP, Chapel Hill, NC, Stockholm, Sweden, Oslo, Norway, Gentofte, Denmark, Liverpool, United Kingdom, Leicester, United Kingdom, Washington, DC, Luton, United Kingdom, Wilmington, DE, Uppsala, Sweden, Cambridge, United Kingdom, Mölndal, Sweden, Kansas City, MO |
Ballroom 20D |
Tuesday |
13-Jun |
10:45 - 11:00 AM |
|
|
REMD-477, a Human Glucagon Receptor (GCGR) Antibody, Reduces Daily Insulin Requirements and Improves Glycemic Control in People with Type 1 Diabetes (T1D) |
JEREMY PETTUS, DOMINIC REEDS, TRICIA SANTOS CAVAIOLA, SCHAFER BOEDER, MICHELLE LEVIN, EDDA CAVA, DUNG THAI, JIM SHI, HAI YAN, EDGAR BAUTISTA, JOHN MCMILLAN, ROBERT R. HENRY, SAMUEL KLEIN, La Jolla, CA, St. Louis, MO, San Diego, CA, Camarillo, CA, Del Mar, CA |
Ballroom 20D |
Tuesday |
13-Jun |
11:00 - 11:15 AM |
|
|
Efficacy and Safety of Oral Basal Insulin: Eight-Week Feasibility Study in People with Type 2 Diabetes (T2DM) |
LEONA PLUM-MÖRSCHEL, TIM HEISE, ERIC ZIJLSTRA, KARSTEN LYBY, KARSTEN WASSERMANN, LISE BRØNDSTED, INGE BIRK HALBERG, Mainz, Germany, Neuss, Germany, Søborg, Denmark |
Ballroom 20D |
Tuesday |
13-Jun |
11:30 - 11:45 AM |
Diabetes Technology
|
Abstract ID |
Abstract Title |
Authors |
Room |
Day |
Date |
Time |
|
A Randomised Controlled Trial of Self-Monitoring of Blood Glucose in Noninsulin-Treated Type 2 Diabetes: The SMBG Study |
SHARON N. PARSONS, STEPHEN D. LUZIO, DAVID R. OWENS, SMBG STUDY GROUP, Swansea, United Kingdom, Cardiff, United Kingdom |
Ballroom 20D |
Saturday |
10-Jun |
8:00 - 8:15 AM |
|
|
|
Sugar.IQ Insights: An Innovative Personalized Machine-Learning Model For Diabetes Management |
PRATIK AGRAWAL, ALEX ZHONG, ANUPAM PHUKAN, BOYI JIANG, TONI CORDERO, HUZEFA NEEMUCHWALA, FRANCINE KAUFMAN, Northridge, CA |
Ballroom 20D |
Saturday |
10-Jun |
8:30 - 8:45 AM |
|
Diabetes Devices and Profiles of the Clinicians Who Prescribe Them |
MOLLY L. TANENBAUM, REBECCA N. ADAMS, REGAN C. BARLEY, SARAH J. HANES, ESTI ITURRALDE, DIANA NARANJO, KELLEE M. MILLER, RICHARD WOOD, KOREY K. HOOD, Palo Alto, CA, Tampa, FL, San Francisco, CA, Stanford, CA |
Ballroom 20D |
Saturday |
10-Jun |
8:45 - 9:00 AM |
|
|
Effect of Continuous Glucose Monitoring on Glycemic Control in Adults Using Multiple Daily Insulin Injections |
DAVID A. PRICE, TONYA RIDDLESWORTH, ROY W. BECK, HOWARD A. WOLPERT, RICHARD M. BERGENSTAL, ANDREW J. AHMANN, San Diego, CA, Tampa, FL, Boston, MA, Minneapolis, MN, Portland, OR |
Ballroom 20D |
Saturday |
10-Jun |
9:00 - 9:15 AM |
|
|
High Wear Time and Improved Accuracy with Implantable Continuous Glucose Monitoring: The PRECISE Trials |
J. HANS DEVRIES, MARK P. CHRISTIANSEN, LYNNE KELLEY, Amsterdam, Netherlands, Walnut Creek, CA, Germantown, MD |
Ballroom 20D |
Saturday |
10-Jun |
9:30 - 9:45 AM |
|
|
Use of Remote Digital Monitoring by Glucose Management Teams in Hospitalized High-Risk Patients to Reduce Hypo- and Hyperglycemia |
MARIA ISABEL GARCIA, LAURA TALAVERA, ADDIE L. FORTMANN, NOEMI ALONSO, REMY BABANTO, TERESA VELA, TAYLOR CLARK, BRITTANY CASTELLANOS, DAVID WINKLER, DANIEL EINHORN, GEORGE E. DAILEY, III, JEFFREY SANDLER, ATHENA PHILIS-TSIMIKAS, San Diego, CA, Del Mar, CA, La Jolla, CA |
Ballroom 20D |
Saturday |
10-Jun |
9:45 - 10:00 AM |
|
|
Effects of a Gamified Mobile Application to Support a Lifestyle-Change Program in Adults: A Controlled Pilot |
SAM ODDSSON, Palo Alto, CA |
5 |
Sunday |
11-Jun |
8:15 - 8:30 AM |
|
|
The Effect of the Patient-Centered, Smartphone-Based, Diabetes Care System in Patients with Uncontrolled Type 2 Diabetes: A Randomized Controlled Trial for 24 Weeks |
EUN KY KIM, SOO HEON KWAK, HYE SEUNG JUNG, BO KYUNG KOO, MIN KYONG MOON, SOO LIM, HAK CHUL JANG, KYONG SOO PARK, YOUNG MIN CHO, Seoul, Korea, Republic of |
5 |
Sunday |
11-Jun |
9:45 - 10:00 AM |
|
|
A Prospective, Pragmatic Clinical Trial to Compare the Real-World Use of V-Go in Type 2 Diabetes Patients |
SCOTT ABBOTT, MATTHEW NGUYEN, POUL STRANGE, MARK CZIRAKY, THOMAS WASSER, KAY LARHOLT, Zionsville, IN, Bridgewater, NJ, Princeton Junction, NJ, Wilmington, DE |
Hall A |
Saturday |
10-Jun |
9:00 - 9:15 AM |
|
|
Remote Interventions Improving Specialty Complex Care (RIISCC) for Patients with Type 2 Diabetes |
LESLIE A. EILAND, MOHAMMAD SIAHPUSH, ROBERT J. SCHWAB, DEJUN SU, TZEYU L. MICHAUD, GERI M. TYSON, MARY E. DEVANY, JENNIFER L. LARSEN, Omaha, NE |
1 |
Sunday |
11-Jun |
4:45 - 5:00 PM |
|
|
Connected Glucose Meter plus Coaching Improves Diabetes Clinical Outcomes and Decreases Costs |
JENNIFER BOLLYKY, CHRIS WHALEY, JENNIFER SCHNEIDER, Mountain View, CA, Santa Monica, CA |
1 |
Monday |
12-Jun |
9:45 - 10:00 AM |
|
|
Artificial Pancreas in an Acute General Hospital: A Randomised Controlled Study |
HOOD THABIT, LIA BALLY, SARA HARTNELL, MALGORZATA E. WILINSKA, YUE RUAN, ANDREA LAKE, SHANNON FARNHAM, JOANNA GREY, HARRIET CHURCHILL, MARK L. EVANS, ANTHONY P. COLL, ROMAN HOVORKA, Cambridge, United Kingdom |
Ballroom 20D |
Monday |
12-Jun |
8:15 - 8:30 AM |
|
|
Inpatient Safety and Feasibility of the Tandem Predictive Low Glucose Suspend (PLGS) Insulin Pump System |
GREGORY P. FORLENZA, PAUL WADWA, ROBERT SLOVER, ROBERT O'BRIEN, THOMAS J. MOUSE, JOHN LUM, CARI BERGET, TATIANA MARCAL, ROY W. BECK, BRUCE A. BUCKINGHAM, TRANG T. LY, Aurora, CO, Tampa, FL, Palo Alto, CA |
Ballroom 20D |
Monday |
12-Jun |
8:45 - 9:00 AM |
|
|
Single and Dual-Hormone Closed-Loop Glucose Control with Automated Exercise Detection to Prevent Hypoglycemia in Type 1 Diabetes |
JESSICA R. CASTLE, JOSEPH EL YOUSSEF, RAVI REDDY, NAVID RESALAT, DEBORAH BRANIGAN, UMA RAJHBEHARRYSINGH, BRIAN SENF, SAMUEL SUGERMAN, NICHOLAS PREISER, PETER G. JACOBS, Portland, OR |
Ballroom 20D |
Monday |
12-Jun |
9:00 - 9:15 AM |
|
|
Insulin Pump Use in Adults with Type 1 Diabetes (T1D): International Comparison with 18,165 Adults from the T1D Exchange (U.S.) and the DPV Initiative (Germany and Austria) |
KELLEE M. MILLER, JULIA M. HERMAN, DAVID M. MAAHS, SABINE E. HOFER, MICHAEL R. RICKELS, MICHAEL HUMMEL, JENNIFER L. SHERR, INGRID SCHÜTZ-FUHRMANN, CLAIRE T. BOYLE, REINHARD W. HOLL, Tampa, FL, Ulm, Germany, Stanford, CA, Innsbruck, Austria, Philadelphia, PA, Rosenheim, Germany, New Haven, CT, Vienna, Austria |
Ballroom 20D |
Monday |
12-Jun |
9:15 - 9:30 AM |
|
|
Closed-Loop Outperforms Threshold-Low-Glucose Suspend Insulin Delivery on Glucose Control in Prepubertal Outpatients with Type 1 Diabetes |
ERIC RENARD, NADIA TUBIANA-RUFI, ELISABETH BONNEMAISON-GILBERT, REGIS COUTANT, FABIENNE DALLA-VALE, ANNE FARRET, AMELIE POIDVIN, NATACHA BOUHOURS-NOUET, CHARLOTTE ABETTAN, JEROME PLACE, MARC D. BRETON, Montpellier, France, Paris, France, Tours, France, Angers, France, Charlottesville, VA |
Ballroom 20D |
Monday |
12-Jun |
9:30 - 9:45 AM |
|
|
Diabeloop Closed-Loop Achieves Better Blood Glucose Control than Sensor-Augmented Pump over Three Days Involving Intensive Physical Exercises, Gastronomic Dinners, or Rest in T1D Patients |
YVES REZNIK, NATHALIE JEANDIDIER, PIERRE YVES BENHAMOU, SOPHIE BOROT, MAEVA DORON, SYLVIA FRANC, HÉLÈNE HANAIRE, ERIK HUNEKER, ERIC RENARD, PAULINE SCHAEPELYNCK, ILHAM XHAARD, ALFRED PENFORNIS, GUILLAUME CHARPENTIER, BRUNO GUERCI, DIABELOOP STUDY GROUP, Caen, France, Strasbourg, France, Grenoble, France, Besancon, France, Corbeil-Essonnes, France, Toulouse, France, Montpellier, France, Marseille, France, Evry, France, Nancy, France |
Ballroom 20D |
Monday |
12-Jun |
9:45 - 10:00 AM |
|
|
Restoration of Hypoglycemia Awareness with Closed-Loop Therapy |
RYAN S. KINGMAN, JESSICA L. ROBIC, BRUCE A. BUCKINGHAM, PAULA CLINTON, BORIS P. KOVATCHEV, STACEY M. ANDERSON, Stanford, CA, Charlottesville, VA |
31 |
Monday |
12-Jun |
4:45 - 5:00 PM |
|
|
Community Health Workers, Mobile Health, or Both for Management of Medicaid Patients with Diabetes |
RICHARD J. KATZ, GAIL NUNLEE-BLAND, MICHELLE F. MAGEE, HEATHER YOUNG, LINDA WITKIN, CARINE NASSAR, JOSHUA L. COHEN, Washington, DC |
31 |
Monday |
12-Jun |
4:30 - 4:45 PM |
|
|
Validation for Artificial Intelligence Leveraging Patient-Centric User Experience for Behavior Change in Subjects with Type 2 Diabetes |
SOSALE R. ARAVIND, BANSHI D. SABOO, TEJAS SHAH, SHILPA S. JOSHI, MAAZ SHAIKH, UTKARSH SUBNIS, ABHISHEK SHAH, JOTHYDEV KESAVADEV, VALUE COLLABORATOR GROUP, Bangalore, India, Ahmedabad, India, Mumbai, India, Trivandrum, India |
31 |
Monday |
12-Jun |
5:00 - 5:15 PM |
|
|
Outcomes of a Telehealth Initiative for Diabetes Management in Primary Care |
ANDERS L. CARLSON, JACKLYN M. KARBAN, CHRISTOPHER T. KODL, JODI M. LAVIN-TOMPKINS, Minneapolis, MN, St. Paul, MN, Bloomington, MN |
31 |
Monday |
12-Jun |
5:30 - 5:45 PM |
|
|
Mobile Diabetes Education for Fathers of Youth with Type 1 Diabetes: mDAD |
ANASTASIA ALBANESE-O’NEILL, MICHAEL J. HALLER, ANGELINA BERNIER, DESMOND SCHATZ, Gainesville, FL |
31 |
Monday |
12-Jun |
5:15 - 5:30 PM |
-- by Helen Gao and Kelly Close